CQ (A): Can urate-lowering agents be recommended in patients with hyperuricemia and kidney injury over non-medication treatment? |
Recommendation |
Direction and strength of the recommendation |
Certainty in evidence |
The use of urate-lowering agents to retard the decline in kidney function is conditionally recommended in patients with hyperuricemia and kidney injury. |
It is conditionally recommended for. |
B (moderate) |
CQ (B): Can urate-lowering agents be recommended for hypertensive patients with hyperuricemia over non-medication treatment? |
Recommendation |
Direction and strength of recommendation |
Certainty in evidence |
The use of urate-lowering agents to improve life prognosis and reduce the risk of cardiovascular disease cannot be actively recommended for hypertensive patients with hyperuricemia |
It is conditionally recommended against. |
D (very weak) |
CQ (C): Can urate-lowering agents be recommended for patients with heart failure and hyperuricemia over non-medication treatment? |
Recommendation |
Direction and strength of recommendation |
Certainty in evidence |
The use of urate-lowering agents to improve life prognosis and reduce the risk of cardiovascular disease cannot be actively recommended for patients with heart failure and hyperuricemia. |
It is conditionally recommended against. |
C (weak) |